Aravive Inc. (ARAV) PT Raised to $31 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Aravive Inc. (ARAV) PT Raised to $28 at Wedbush
November 20, 2019 12:12 PM ESTWedbush analyst David Nierengarten raised the price target on Aravive Inc. (NASDAQ: ARAV) to $28.00 (from $12.00) while maintaining a Outperform rating.
... MoreAravive Inc. (ARAV) PT Raised to 'Street High' $36 at Piper Jaffray
November 20, 2019 10:34 AM ESTPiper Jaffray analyst Edward Tenthoff raised the price target on Aravive Inc. (NASDAQ: ARAV) to $36.00 (from $15.00) while maintaining a Overweight rating.
... MoreAravive Inc. (ARAV) Halted on LUDP
November 20, 2019 9:46 AM ESTAravive Inc. (NASDAQ: ARAV) Halted on LUDP
... MorePre-Open 11/20: (ARAV) (I) (TGT) Higher (PDD) (URBN) (MUX) Lower (more...)
November 20, 2019 9:16 AM ESTToday's Pre-Open Movers
Aravive, Inc. (Nasdaq: ARAV) 214.9% HIGHER; announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients. The data from the first 31 patients treated at the 10mg/kg dose are maturing and affirm earlier findings on the relationship between AVB-500 levels and anti-tumor response. In this data analysis, high serum drug levels of AVB-500 were strongly predictive of anti-tumor activity with statistically significant correlation to progression-free survival (PFS; p=0.0066). PFS is the primary endpoint for... More
Aravive Inc. (ARAV) Extends Gain, Up 250%
November 20, 2019 7:43 AM ESTAravive Inc. (NASDAQ: ARAV) Extends Gain, Up 250%
Aravive Inc. (ARAV) Climbs 80% After Positive Data from Ongoing Trial of AVB-500 in Ovarian Cancer
November 20, 2019 7:21 AM ESTAravive Inc. (NASDAQ: ARAV) Climbs 80% After Positive Data from Ongoing Trial of AVB-500 in Ovarian Cancer
... MoreAravive (ARAV) Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer
November 20, 2019 7:02 AM ESTAravive, Inc. (Nasdaq: ARAV) today announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients. The data from the first 31 patients treated at the 10mg/kg dose are maturing and affirm earlier findings on the relationship between AVB-500 levels and anti-tumor response. In this data analysis, high serum drug levels of AVB-500 were strongly predictive of anti-tumor activity with statistically significant correlation to progression-free survival (PFS; p=0.0066). PFS is the primary endpoint for platinum-resistant ovarian cancer clinical... More
